There's an article in the New York Times about the BIOSECURE Act, and its impact with WuXi on the general pharmaceutical market. This is the only relevant portion (I feel):
Last month, after a classified briefing with intelligence staff, the Senate homeland security committee advanced a bill by a vote of 11 to 1: It would bar companies from receiving government contracts for work with Wuxi, but would allow the companies to still obtain contracts for unrelated projects. Government contracts with drugmakers are generally limited, though they were worth billions of dollars in revenue to companies that responded to the Covid-19 pandemic.
The real question is 1) will a bill pass, and 2) what will the bill look like? If the Senate version looks like this (i.e. banning the government from working directly with WuXi, but not stopping pharma companies from working with WuXi), I suspect this is going to not be particularly impactful.
No comments:
Post a Comment
looks like Blogger doesn't work with anonymous comments from Chrome browsers at the moment - works in Microsoft Edge, or from Chrome with a Blogger account - sorry! CJ 3/21/20